- DJT Plants Limited (100%). DJT Plants has a Home Office licence to grow high (>0.2%) THC cannabis for research purposes. Ananda acquired full ownership of DJT Plants in December 2022 after acquiring the remaining shares from JEPCO Group, which had previously grown medical cannabis for the pharmaceutical industry under a similar Home Office licence.
- MRX Medical Limited (100%). MRX has invented a proprietary method to formulate cannabis medicines, the first of which, MRX1, is to be used in two Phase II Randomised Controlled Trials (RCTs) to investigate the effectiveness of cannabidiol (CBD) in chemotherapy induced peripheral neuropathy (CIPN) and in patients with endometriosis. MRX’s cannabidiol formulations meet the requirements set out by the National Institute for Health and Care Excellence (NICE)for research into the effectiveness of CBD with no or trace tetrahydrocannabinol (THC). MRX1 and MRX2, MRX’s second formulation, will also be launched as unlicensed CBPM’s (Cannabis Based Products for Medicinal use) in the coming months. The clinical trials have received combined commitments of £1.55m in external grant funding and will be carried out by leading investigators at the University of Edinburgh.